Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xianglei Tangzu Gao in Wagner Grade II Diabetic Foot Ulcers
NCT06531512Phase 3Active, not recruiting
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Botanical drug
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing Xianglei Tangzu Gao plus Standard of Care with Vehicle Cream plus Standard of Care (2 arms). Primary endpoint: Proportion of subjects with complete closure of Target Ulcer at 16 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
Fespixon
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06531512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531512.